Latest Breaking News On - டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் போஸ்டன் - Page 2 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses Allarity Therapeutics A/SDecember 14, 2020 GMT Press Release       Hørsholm, Denmark (14 December 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has amended its license agreement with Eisai Co., Ltd. (Tokyo, Japan) to expand Allarity’s field-of-use to include anti-viral uses of Stenoparib (formerly E7449). Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment.  With the amendment to the license, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.

United statesThomas pedersonStever carchediMike beyerEisai co ltdDana farber cancer institute bostonCarrotize pr communicationsSam brown incPress releaseAllarity therapeuticsOperation warpDana farber cancer instituteDrug response predictorNasdaq first north growth market stockholmஒன்றுபட்டது மாநிலங்களில்தாமஸ் பேதேர்சோன்